| Title: | Dose-finding and efficacy confirmation trial of the superselective intra-arterial infusion of cisplatin and concomitant radiotherapy for locally advanced maxillary sinus cancer (Japan Clinical Oncology Group 1212) : Dose-finding phase |
| Other Titles: | A dose-finding and efficacy confirmation trial of the superselective intra-arterial infusion of cisplatin and concomitant radiotherapy for locally advanced maxillary sinus cancer (JCOG1212) : dose-finding phase |
| Intra-arterial CRT for maxillary sinus cancer |
| Authors: | Homma, Akihiro Browse this author →KAKEN DB |
| Onimaru, Rikiya Browse this author →KAKEN DB |
| Matsuura, Kazuto Browse this author →KAKEN DB |
| Shinomiya, Hirotaka Browse this author |
| Sakashita, Tomohiro Browse this author →KAKEN DB |
| Shiga, Kiyoto Browse this author →KAKEN DB |
| Tachibana, Hiroyuki Browse this author |
| Nakamura, Kenichi Browse this author |
| Mizusawa, Junki Browse this author |
| Kitahara, Hideaki Browse this author |
| Eba, Junko Browse this author |
| Fukuda, Haruhiko Browse this author |
| Fujii, Masato Browse this author →KAKEN DB |
| Hayashi, Ryuichi Browse this author |
| Keywords: | chemoradiotherapy |
| cisplatin |
| intra-arterial |
| maxillary sinus cancer |
| squamous cell carcinoma |
| Issue Date: | Mar-2018 |
| Publisher: | John Wiley & Sons |
| Journal Title: | Head & neck |
| Volume: | 40 |
| Issue: | 3 |
| Start Page: | 475 |
| End Page: | 484 |
| Publisher DOI: | 10.1002/hed.25001 |
| PMID: | 29130565 |
| Abstract: | BACKGROUND: We are currently undertaking a multi-institutional prospective trial of the superselective intra-arterial infusion of high-dose cisplatin with concomitant radiotherapy for patients with T4aN0M0 or T4bN0M0 locally advanced maxillary sinus squamous cell carcinomas (MS-SCC). We herein report the results of the dose-finding phase. METHODS: The dose-finding phase sought to evaluate the incidence of dose-limiting toxicities (DLTs) and determine the recommended number of cycles (RC) of the intra-arterial infusion of cisplatin. In this phase, 100 mg/m2 of cisplatin was administered intra-arterially weekly for 7 weeks with concomitant radiotherapy (70 Gy). RESULTS: All 18 patients received a full dose of radiotherapy. The number of cycles of cisplatin was 7 in 13 patients and 6 in 5 patients. DLT was observed in 5 patients. CONCLUSIONS: These results indicated that this therapy is safe and well-tolerated at 7 cycles of cisplatin, which was determined to be the RC for locally advanced MS-SCC. |
| Rights: | This is the peer reviewed version of the following article: Homma A, Onimaru R, Matsuura K, et al. Dose-finding and efficacy confirmation trial of the superselective intra‐arterial infusion of cisplatin and concomitant radiotherapy for locally advanced maxillary sinus cancer (Japan Clinical Oncology Group 1212): Dose-finding phase. Head & Neck. 2018;40:475–484, which has been published in final form at https://doi.org/10.1002/hed.25001. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. |
| Type: | article (author version) |
| URI: | http://hdl.handle.net/2115/72733 |
| Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
